Patent ID: 9556266
Date: 2017-01-31
CPC Classifications: A61P,C07K

Claim:
1. A method of treating sickle cell disease in a subject, the method comprising administering a therapeutically effective dose of a humanized antibody or binding fragment thereof to the subject, the humanized antibody or binding fragment thereof comprising a light chain variable region comprising, in sequential order, a first light chain complementary determining region (CDR) having the sequence KASQSVDYDGHSYMN (SEQ ID NO: 1), a second light chain CDR having the sequence AASNLES (SEQ ID NO: 2), and a third light chain CDR having the sequence QQSDENPLT (SEQ ID NO: 3); and a heavy chain variable region comprising, in sequential order, a first heavy chain CDR having the sequence SYDIN (SEQ ID NO: 4), a second heavy chain CDR having the sequence WIYPGDGSIKYNEKFKG (SEQ ID NO: 5), and a third heavy chain CDR having the sequence RGEYGNYEGAMDY (SEQ ID NO: 6); and wherein the first, second, and third light chain CDRs are within a framework region of a humanized light chain variable region and wherein the first, second, and third heavy chain CDRs are within a framework region of a humanized heavy chain variable region; wherein the humanized antibody or binding fragment binds P-selectin with a dissociation constant between 10 wherein the effective dose of the humanized antibody or binding fragment treats the sickle cell disease.